We found that sorafenib could effectively inhibite phosphorylation of both AKT and ERK in a PDGFRβ-dependent manner, and subsequently enhance the anti-tumor sensitivity of rapamycin in vitro and in an immunocompetent orthotopic rat HCC model. Here, AKT1 is linked to neoplasm.